# Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)

> **NCT01146262** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nantes University Hospital** · enrollment: 5 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **OTHER:** cell therapy product
- **PROCEDURE:** injection of the cell therapy product

## Key facts

- **NCT ID:** NCT01146262
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-11
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146262, "Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01146262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*